| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6057307 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US5889015 | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
| US6677323 | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jan, 2014
(10 years ago) | |
|
US5889015 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating lower airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
|
US6057307 (Pediatric) | ORGANON LLC | Use of mometasone furoate for treating airway passage and lung diseases |
Jul, 2014
(9 years ago) | |
| US6068832 | ORGANON LLC | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
Aug, 2017
(6 years ago) | |
| US7566705 | ORGANON LLC | Combination of formoterol and mometasone furoate for asthma |
May, 2020
(3 years ago) | |
| US7067502 | ORGANON LLC | Combinations of formoterol and mometasone furoate for asthma |
May, 2020
(3 years ago) | |
|
US7566705 (Pediatric) | ORGANON LLC | Combination of formoterol and mometasone furoate for asthma |
Nov, 2020
(3 years ago) | |
|
US7067502 (Pediatric) | ORGANON LLC | Combinations of formoterol and mometasone furoate for asthma |
Nov, 2020
(3 years ago) | |
Dulera is owned by Organon Llc.
Dulera contains Formoterol Fumarate; Mometasone Furoate.
Dulera has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Dulera are:
- US6057307
- US5889015
- US6677323
- US5889015*PED
- US6057307*PED
- US6068832
- US7566705
- US7067502
- US7566705*PED
- US7067502*PED
Dulera was authorised for market use on 12 August, 2019.
Dulera is available in aerosol, metered;inhalation dosage forms.
Dulera can be used as treatment of asthma.
The generics of Dulera are possible to be released after 12 August, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-214) | Dec 20, 2020 |
| New Strength(NS) | Aug 12, 2022 |
| Pediatric Exclusivity(PED) | Jun 20, 2021 |
| New Combination(NC) | Jun 22, 2013 |
Drugs and Companies using FORMOTEROL FUMARATE; MOMETASONE FUROATE ingredient
Market Authorisation Date: 12 August, 2019
Treatment: Treatment of asthma
Dosage: AEROSOL, METERED;INHALATION
DULERA family patents
